Mumbai, Dec. 17 -- The EIR was issued following an inspection of the facility from 08 September 2025 to 16 September 2025.

Nilesh Gupta, managing director, Lupin, said: "We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility.

We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence."

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharm...